AstraZeneca Adds Lung-Drug Offerings With Almirall Deal

AstraZeneca, the U.K. drugmaker that resisted a Pfizer Inc. takeover attempt, is building up its respiratory business by buying the rights to Almirall lung medicines for $875 million.
Bloomberg